| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/26/2004 | WO2004003188A3 Stabilization of granules |
| 02/26/2004 | WO2004003010A3 Nuclear hormone receptor ligano-binding domain containing protein |
| 02/26/2004 | WO2004003009A3 Francisella tularensis immunogenic proteins and dna encoding these |
| 02/26/2004 | WO2004000881A9 Dna sequence and recombinant production of the grass pollen allergen phl p4 |
| 02/26/2004 | WO2004000237A3 Enhancing treatment of mdr cancer with adenosine a3 antagonists |
| 02/26/2004 | WO2003105777A3 Fiber cell globulization aminopeptidases and methods for treating or preventing cataracts |
| 02/26/2004 | WO2003104477A3 BLOCKING ADIPOCYTE DIFFERENTIATION AND TRIGLYCERIDE ACCUMULATION USING Dp-1 INHIBITORS |
| 02/26/2004 | WO2003104437A3 Anti-addl antibodies and uses thereof |
| 02/26/2004 | WO2003104217A3 Prodrugs of excitatory amino acids |
| 02/26/2004 | WO2003099204A3 Antisense modulation of inhibitor-kappa b kinase-beta expression |
| 02/26/2004 | WO2003098991A3 Employment of rotavirus proteins, derived proteins and peptides for the modulation of tissue permeability |
| 02/26/2004 | WO2003098223A3 A method for killing cells by inhibiting histone activity in the cell |
| 02/26/2004 | WO2003097688A3 Muteins of placental growth factor type 1, preparation method and application thereof |
| 02/26/2004 | WO2003096991A3 Amelioration of the development of cataracts and other opthalmic diseases |
| 02/26/2004 | WO2003096973A3 A direct cellular energy delivery system |
| 02/26/2004 | WO2003096020A3 Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8) |
| 02/26/2004 | WO2003095652A3 Expression constructs for producing double-stranded (ds) rna and the use thereof |
| 02/26/2004 | WO2003095474A3 Peptides and methods for the control of obesity |
| 02/26/2004 | WO2003094950A3 A method of inhibiting the emigration of cells from the intravascular compartment into tissues |
| 02/26/2004 | WO2003094862A3 tRNA SYNTHASE: MODULATORS OF ANGIOGENESIS |
| 02/26/2004 | WO2003091387A9 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands |
| 02/26/2004 | WO2003089590A3 TRANSIENT AND/OR PERMANENT MODIFICATION OF SEXUAL BEHAVIOR AND/OR FERTILITY USING RECOMBINANT CHIMERIC GnRH |
| 02/26/2004 | WO2003087345A3 Stimulation of nerve cell regeneration |
| 02/26/2004 | WO2003086491A3 Tissue defect dressings comprising a keratin network |
| 02/26/2004 | WO2003086296A3 Treatment for type 1 diabetes before and after expression of predisposition markers. |
| 02/26/2004 | WO2003083117A3 Vascularization controlling gene |
| 02/26/2004 | WO2003083050A3 Human deubiquitinating protease gene on chromosome 7 and its murine ortholog |
| 02/26/2004 | WO2003082209A3 Cochleates made with purified soy phosphatidylserine |
| 02/26/2004 | WO2003079978A3 Protease activity of thrombin inhibits angiogenesis |
| 02/26/2004 | WO2003073998A3 Local production and/or delivery of anti-cancer agents by stromal cell precursors |
| 02/26/2004 | WO2003073982A3 Anti-interleukin-1 beta analogs |
| 02/26/2004 | WO2003072745A3 Antigene locks and therapeutic uses thereof |
| 02/26/2004 | WO2003068805A3 Formulation strategies in stabilizing peptides in organic solvents and in dried states |
| 02/26/2004 | WO2003068156A3 Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome |
| 02/26/2004 | WO2003063769A3 Vesicle-associated proteins |
| 02/26/2004 | WO2003062401A3 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| 02/26/2004 | WO2003060085A3 Mammalian neural stem cells, compositions and uses thereof |
| 02/26/2004 | WO2003060071A3 Albumin fusion proteins |
| 02/26/2004 | WO2003059898A3 Eponemycin and epoxomicin analogs and uses thereof |
| 02/26/2004 | WO2003057829A3 Methods of generating multispecific, multivalent agents from vh and vl domains |
| 02/26/2004 | WO2003057822A3 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| 02/26/2004 | WO2003057144A3 Change inhibitors of dipeptidyl peptidase iv |
| 02/26/2004 | WO2003054147A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 02/26/2004 | WO2003051837A3 Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr) |
| 02/26/2004 | WO2003049684A3 Pseudo-antibody constructs |
| 02/26/2004 | WO2003048333A3 Endorepellin compositions and methods for inhibiting angiogenesis |
| 02/26/2004 | WO2003048331A3 Antisense modulation of phospholipid scramblase 4 expression |
| 02/26/2004 | WO2003047530A3 Storage-stable fibrin sealant |
| 02/26/2004 | WO2003045334A3 Methods and compositions for ameliorating the undesirable effects of chemotherapy |
| 02/26/2004 | WO2003044175A3 Methods and use of motoneuronotropic factors |
| 02/26/2004 | WO2003043586A9 Compositions for sustained action product delivery |
| 02/26/2004 | WO2003040346A3 Methods and compositions for the use of stromal cells to support embryonic and adult stem cells |
| 02/26/2004 | WO2003040325A3 Novel proteins and nucleic acids encoding same |
| 02/26/2004 | WO2003039476A3 Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 |
| 02/26/2004 | WO2003039474A3 Method and composition for the modulation of angiogenesis |
| 02/26/2004 | WO2003038058A3 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema |
| 02/26/2004 | WO2003034993A3 Composition and method for growing, protecting, and healing tissues and cells |
| 02/26/2004 | WO2003029495A3 Coniosulphides and their derivatives, method for their production and use as medicaments |
| 02/26/2004 | WO2003029412A3 Restricted expression lentivial vectors |
| 02/26/2004 | WO2003022212A3 Anti-tumor effects of prostate carcinoma tumor antigen-1 |
| 02/26/2004 | WO2003020892A3 Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY |
| 02/26/2004 | WO2003018516A3 Glucagon-like peptide-1 analogs |
| 02/26/2004 | WO2003016472A9 Hybrid interferon/interferon tau proteins, compositions and methods of use |
| 02/26/2004 | WO2003015708A3 Composition and method for treating hiv infection |
| 02/26/2004 | WO2003011892A3 Glp-1 exendin-4 peptide analogs and uses thereof |
| 02/26/2004 | WO2003008449A8 Ntb-a, a surface molecule involved in natural killer cells activity |
| 02/26/2004 | WO2003007733A8 Protein-containing foodstuff comprising a cross-linking enzyme and a hydrocolloid |
| 02/26/2004 | WO2003006641A9 Epsti1, a gene induced by epithelial-stromal interaction in human breast cancer |
| 02/26/2004 | WO2002103014A3 Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells |
| 02/26/2004 | WO2002102973A3 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| 02/26/2004 | WO2002099061A3 Method of treating alzheimer's disease with se-containing peptide |
| 02/26/2004 | WO2002098424B1 Novel anti-infectives |
| 02/26/2004 | WO2002087419A3 Biological pacemaker |
| 02/26/2004 | WO2002083917A8 Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer |
| 02/26/2004 | WO2002083067A9 Prodrugs via acylation with cinnamate |
| 02/26/2004 | WO2002074808A3 Modified insulin with reduced immunogenicity |
| 02/26/2004 | WO2002069988A3 Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and their use in bone marrow transplantation |
| 02/26/2004 | WO2002062204A3 Methods for diagnosing and treating heart disease |
| 02/26/2004 | WO2002057440A9 Screens and assays for agents useful in controlling parasitic nematodes |
| 02/26/2004 | WO2002053172A3 Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover |
| 02/26/2004 | WO2002051237A3 Helicobacter proteins, nucleic acids and uses thereof |
| 02/26/2004 | WO2002050277A3 Protein and nucleic acids encoding same |
| 02/26/2004 | WO2002048369A3 Polynucleotide encoding a human potassium channel beta-subunit, k+mbeta1 |
| 02/26/2004 | WO2002048345A3 Transgenic mice containing glutamate receptor (grik5) gene disruptions |
| 02/26/2004 | WO2002046418A3 Lipid-associated molecules |
| 02/26/2004 | WO2002046382A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 02/26/2004 | WO2002045498A3 Transgenic mice containing channel protein target gene disruptions |
| 02/26/2004 | WO2002045496A3 Transenic mice containing frp-rs4 gene disruptions |
| 02/26/2004 | WO2002045494A3 Transgenic mice containing glucagon receptor gene disruptions |
| 02/26/2004 | WO2002045492A3 Transgenic mice containing polycystin-related gene disruptions |
| 02/26/2004 | WO2002042420A3 Modulation of gene expression during intimal hyperplasia of the carotid artery |
| 02/26/2004 | WO2002042336A3 Fgf-affinity chromatography |
| 02/26/2004 | WO2002041910A8 Methods and compositions for the treatment of diseases of the eye |
| 02/26/2004 | WO2002040656A3 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, and 84234, novel human guanine nucleotide dissociation stimulator, glycosyltransferase, dead type helicase, centaurin, dehydrogenase/reductase, and metal transporter family members and uses thereof |
| 02/26/2004 | WO2002038775A3 METHODS FOR PRODUCING AND PURIFYING RECOMBINANT α-L-IDURONIDASE |
| 02/26/2004 | WO2002034782A3 Endozepine-like polypeptide nov1 and nucleic acid encoding the same |
| 02/26/2004 | WO2002033089A3 Ixodes scapularis tissue factor pathway inhibitor |
| 02/26/2004 | WO2002031152A3 Intracellular signaling molecules |
| 02/26/2004 | WO2002006480A3 Tissue inhibitors of matrix metalloproteinases |
| 02/26/2004 | WO2001057175A3 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides |